Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 20Advanced Solid Tumors 14Solid Tumor 9Solid Tumors 8Advanced Solid Tumor 4Triple Negative Breast Neoplasms 2Neoplasms 2Mesothelioma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Solid Tumor Cancer 1Small Cell Lung Carcinoma 1Selected Subjects With Advanced Solid Tumors 1Prostatic Neoplasms 1Neoplasm Metastasis 1NSCLC 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Mesothelioma, Malignant 1Melanoma 1Malignant Solid Tumor 1Lung Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Docetaxel 1Carcinoma, Transitional Cell 1Advanced Solid Tumour 1Advanced Solid Tumor Cancer 1

Interventions

pembrolizumab 3Ramucirumab 2Nivolumab 2etirinotecan pegol 1cemiplimab 1Ribavirin 1Paclitaxel 1Injections 1Fluorouracil 1Docetaxel 1Decitabine 1Cisplatin 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumor × Docetaxel × Other solid neoplasm × Clear all
NCT01567163 2014-10-16

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

Eli Lilly and Company

Phase 2 Completed
22 enrolled 15 charts
Other solid neoplasm

Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡